Silexion Therapeutics’ SIL-204 shows potential to transform pancreatic cancer treatment

Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotechnology company specializing in RNA interference (RNAi) therapies, has reported promising preclinical results for its next-generation therapeutic candidate, ... Read More